Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Ciudad de Buenos Aires, Argentina | Recruiting |
| Research Site | Ciudad de Buenos Aires, Argentina | Recruiting |
| Research Site | La Plata, Argentina | Recruiting |
| Research Site | Rosario, Argentina | Recruiting |
| Research Site | San Juan Bautista, Argentina | Recruiting |
| Research Site | Santa Fe, Argentina | Withdrawn |
| Research Site | Clayton, Australia | Recruiting |
| Research Site | Heidelberg, Australia | Recruiting |
| Research Site | Nedlands, Australia | Recruiting |
| Research Site | Wollongong, Australia | Recruiting |
| Research Site | Barretos, Brazil | Recruiting |
| Research Site | Belo Horizonte, Brazil | Recruiting |
+ 66 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07160608